View ValuationPentixapharm Holding 향후 성장Future 기준 점검 0/6Pentixapharm Holding 의 수익은 연간 13.4% 감소할 것으로 예상되는 반면, 연간 수익은 65.6% 로 증가할 것으로 예상됩니다. EPS는 연간 13.3% 만큼 쇠퇴할 것으로 예상됩니다.핵심 정보-13.4%이익 성장률-13.32%EPS 성장률Medical Equipment 이익 성장17.1%매출 성장률65.6%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트15 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 10Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary AldosteronismPentixapharm Holding AG received notice from the U.S. Food and Drug Administration (FDA) that Fast Track designation has been granted to its development candidate [68Ga]Ga-PentixaFor for the diagnosis of patients with hypertension and underlying primary aldosteronism. In its notification, the FDA determined that Pentixapharm's request meets the criteria for Fast Track designation and that [68Ga]Ga-PentixaFor is accordingly designated as a Fast Track product for the diagnostic subtyping of adult patients with confirmed primary aldosteronism. Fast Track designation is intended to facilitate the development and review of products that address serious conditions and have the potential to fill an unmet medical need. It provides opportunities for more frequent interaction with the FDA during development and may support a more efficient regulatory review process if the relevant criteria are met. The practical benefit of Fast Track designation lies above all in closer and more frequent interaction with the FDA, allowing development and submission questions to be clarified early and the regulatory process to be prepared efficiently. The FDA's specific designation relates to the diagnostic subtyping of adult patients with already confirmed primary aldosteronism, precisely the clinical decision point at which physicians must distinguish between potential surgical treatment and long-term medical therapy. The designation follows Pentixapharm's recent announcement that the Investigational New Drug (IND) application for the U.S. Phase 3 PANDA study of [68Ga]Ga-PentixaFor became effective following the FDA's 30-day review period, with the FDA allowing the study to proceed (“Study May Proceed”). [68Ga]Ga-PentixaFor addresses a central diagnostic bottleneck in primary aldosteronism and hypertension: non-invasive subtyping to guide the treatment decision between surgery and chronic medical therapy. Pentixapharm is preparing to initiate its pivotal Phase 3 PANDA study in the United States. PANDA is designed to evaluate [68Ga]Ga-PentixaFor PET/CT as a non-invasive imaging approach to help identify patients with unilateral primary aldosteronism. This distinction is clinically important because unilateral disease may be treated with surgical removal of the affected adrenal gland in selected patients, while bilateral disease generally requires long-term medical therapy. Primary aldosteronism is one of the most common and substantially underdiagnosed causes of secondary hypertension. The condition occurs when one or both adrenal glands produce too much aldosterone, a hormone that can drive high blood pressure and increase cardiovascular risk. For patients, the key treatment question is not only whether primary aldosteronism is present, but whether excess aldosterone production is coming from one adrenal gland or both. This makes accurate subtyping central to treatment selection and creates a major diagnostic bottleneck in the current care pathway. [68Ga]Ga-PentixaFor is designed to target CXCR4, a biological receptor shown to be strongly expressed in aldosterone-producing adrenal lesions. By visualizing CXCR4 expression with PET/CT, Pentixapharm aims to support a more precise and patient-friendly diagnostic pathway that can help physicians guide patients toward the appropriate treatment option. [68Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [68Ga]Ga-PentixaFor PET/CT in more than 2,000 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo. Pentixapharm is evaluating this established CXCR4 imaging approach in primary aldosteronism, where molecular characterization of adrenal lesions may help address limitations of conventional anatomical imaging. Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, supporting its potential relevance for identifying unilateral disease. Primary aldosteronism (PA) is increasingly recognized as one of the most common and significantly underdiagnosed endocrine disorders worldwide and a leading cause of secondary hypertension. Recent international and Endocrine Society guidelines have expanded recommendations for PA screening, reflecting growing evidence that the disease may affect approximately 5–10% of all patients with hypertension and up to 20–30% of those with treatment-resistant hypertension. Given the high prevalence of hypertension in the United States and globally, even modest improvements in PA detection and subtyping could translate into a meaningfully larger diagnosed and treatment-directed patient population. As awareness, screening, and targeted treatment options continue to advance, the diagnostic landscape for PA is undergoing a fundamental transformation. This shift has the potential to expand the addressable patient population from a highly selected subgroup to millions of patients globally, creating a substantial opportunity for innovative diagnostic approaches aimed at improving disease detection, patient stratification, and treatment selection.공고 • Jul 03Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million.Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 11,020,212 Price\Range: €1.85 Transaction Features: Rights Offering이익 및 매출 성장 예측OTCPK:PTPD.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028N/A-24-15-20212/31/2027N/A-23-21-19212/31/2026N/A-22-10-1723/31/20260-16-15-15N/A12/31/20251-17-19-18N/A9/30/20252-26-24-22N/A6/30/2025-1-20-13-13N/A3/31/20251-16-10-10N/A1/1/20252-13-7-7N/A6/30/20244-5-11-7N/A3/31/20247-8-7-2N/A12/31/20237-8-32N/A12/31/20224-2-6-2N/A12/31/20213-2-4-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: PTPD.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: PTPD.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: PTPD.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: PTPD.F 은(는) 내년에 수익이 없을 것으로 예상됩니다.고성장 매출: PTPD.F 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: PTPD.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 21:39종가2026/06/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pentixapharm Holding AG는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Roger BeckerBankM AGSimon KellerNuWays AG
공고 • Jul 10Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary AldosteronismPentixapharm Holding AG received notice from the U.S. Food and Drug Administration (FDA) that Fast Track designation has been granted to its development candidate [68Ga]Ga-PentixaFor for the diagnosis of patients with hypertension and underlying primary aldosteronism. In its notification, the FDA determined that Pentixapharm's request meets the criteria for Fast Track designation and that [68Ga]Ga-PentixaFor is accordingly designated as a Fast Track product for the diagnostic subtyping of adult patients with confirmed primary aldosteronism. Fast Track designation is intended to facilitate the development and review of products that address serious conditions and have the potential to fill an unmet medical need. It provides opportunities for more frequent interaction with the FDA during development and may support a more efficient regulatory review process if the relevant criteria are met. The practical benefit of Fast Track designation lies above all in closer and more frequent interaction with the FDA, allowing development and submission questions to be clarified early and the regulatory process to be prepared efficiently. The FDA's specific designation relates to the diagnostic subtyping of adult patients with already confirmed primary aldosteronism, precisely the clinical decision point at which physicians must distinguish between potential surgical treatment and long-term medical therapy. The designation follows Pentixapharm's recent announcement that the Investigational New Drug (IND) application for the U.S. Phase 3 PANDA study of [68Ga]Ga-PentixaFor became effective following the FDA's 30-day review period, with the FDA allowing the study to proceed (“Study May Proceed”). [68Ga]Ga-PentixaFor addresses a central diagnostic bottleneck in primary aldosteronism and hypertension: non-invasive subtyping to guide the treatment decision between surgery and chronic medical therapy. Pentixapharm is preparing to initiate its pivotal Phase 3 PANDA study in the United States. PANDA is designed to evaluate [68Ga]Ga-PentixaFor PET/CT as a non-invasive imaging approach to help identify patients with unilateral primary aldosteronism. This distinction is clinically important because unilateral disease may be treated with surgical removal of the affected adrenal gland in selected patients, while bilateral disease generally requires long-term medical therapy. Primary aldosteronism is one of the most common and substantially underdiagnosed causes of secondary hypertension. The condition occurs when one or both adrenal glands produce too much aldosterone, a hormone that can drive high blood pressure and increase cardiovascular risk. For patients, the key treatment question is not only whether primary aldosteronism is present, but whether excess aldosterone production is coming from one adrenal gland or both. This makes accurate subtyping central to treatment selection and creates a major diagnostic bottleneck in the current care pathway. [68Ga]Ga-PentixaFor is designed to target CXCR4, a biological receptor shown to be strongly expressed in aldosterone-producing adrenal lesions. By visualizing CXCR4 expression with PET/CT, Pentixapharm aims to support a more precise and patient-friendly diagnostic pathway that can help physicians guide patients toward the appropriate treatment option. [68Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [68Ga]Ga-PentixaFor PET/CT in more than 2,000 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo. Pentixapharm is evaluating this established CXCR4 imaging approach in primary aldosteronism, where molecular characterization of adrenal lesions may help address limitations of conventional anatomical imaging. Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, supporting its potential relevance for identifying unilateral disease. Primary aldosteronism (PA) is increasingly recognized as one of the most common and significantly underdiagnosed endocrine disorders worldwide and a leading cause of secondary hypertension. Recent international and Endocrine Society guidelines have expanded recommendations for PA screening, reflecting growing evidence that the disease may affect approximately 5–10% of all patients with hypertension and up to 20–30% of those with treatment-resistant hypertension. Given the high prevalence of hypertension in the United States and globally, even modest improvements in PA detection and subtyping could translate into a meaningfully larger diagnosed and treatment-directed patient population. As awareness, screening, and targeted treatment options continue to advance, the diagnostic landscape for PA is undergoing a fundamental transformation. This shift has the potential to expand the addressable patient population from a highly selected subgroup to millions of patients globally, creating a substantial opportunity for innovative diagnostic approaches aimed at improving disease detection, patient stratification, and treatment selection.
공고 • Jul 03Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million.Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 11,020,212 Price\Range: €1.85 Transaction Features: Rights Offering